Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Complement System

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Pharmaceutical Poisoning: Treatment Strategies

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Role of Complement in Myocardial Infarction Reperfusion Injury: An Underappreciated Therapeutic Target.

Frontiers in cell and developmental biology·2021

Same author

Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.

Toxicon : official journal of the International Society on Toxinology·2020

Same author

Addressing Cancer Health Disparities in the Pacific Peoples of Hawai'i, Guam, and the US Associated Pacific Islands Through Pacific-Focused Research Capacity Building.

JCO global oncology·2020

Same author

A Unique Partnership Between the University of Hawai'i Cancer Center and the University of Guam: Fifteen Years of Addressing Cancer Health Disparities in Pacific Islanders in Hawai'i and Guam.

Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health·2019

Same author

Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.

Toxicon : official journal of the International Society on Toxinology·2019

Same author

Absence of a neutralizing antibody response to humanized cobra venom factor in mice.

Molecular immunology·2018

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.

Carl-Wilhelm Vogel¹, David C Fritzinger

¹Cancer Research Center of Hawaii, University of Hawaii at Manoa, Honolulu, Hawaii 96813, USA. cvogel@crch.hawaii.edu

Current Pharmaceutical Design

|November 6, 2007

Summary

This summary is machine-generated.

Cobra Venom Factor (CVF) depletes serum complement by forming a stable C3/C5 convertase. Modified human C3 proteins, or "humanized CVF," offer a promising biopharmaceutical approach for therapeutic complement depletion.

More Related Videos

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA₂

Published on: September 26, 2025

Depletion of Specific Cell Populations by Complement Depletion

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

Related Experiment Videos

Last Updated: Jul 10, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA₂

Published on: September 26, 2025

Depletion of Specific Cell Populations by Complement Depletion

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

Area of Science:

Biochemistry
Immunology
Pharmacology

Background:

Cobra Venom Factor (CVF) is a complement-activating protein from cobra venom.
CVF acts as a structural and functional analog of human complement component C3.
CVF forms a stable and control-resistant C3/C5 convertase in serum, leading to complement depletion.

Purpose of the Study:

To explore CVF as a tool for studying complement's biological functions and role in disease.
To investigate CVF's potential for targeted complement activation via antibody conjugation.
To develop novel biopharmaceuticals for therapeutic complement depletion.

Main Methods:

Utilizing the structural homology between CVF and C3.
Creating hybrid proteins by exchanging sequence portions between C3 and CVF.
Developing
humanized CVF
proteins based on human C3.

Main Results:

CVF enables continuous activation of C3 and C5, resulting in serum complement depletion.
CVF can be safely administered to vertebrate animals.
Hybrid human C3-CVF proteins exhibit the ability to form a stable convertase.

Conclusions:

CVF is a valuable tool for complement research and potential therapeutic intervention.
Engineered human C3 derivatives (
humanized CVF
) represent a promising biopharmaceutical strategy.
Targeted complement depletion using CVF-based therapeutics holds potential for treating complement-mediated diseases.